Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

            


Working Groups – Q2 2024 Summary 

Welcome to the PHUSE Quarter 2 Working Group Report.  The second quarter of the year has been very busy for all Working Groups, with a lot of activity including new deliverables and events.

The Optimizing the Use of Data Standards Working Group are pleased to welcome two new Leads to the team: Sandra VanPelt Nguyen and Edwin van Stein.Sandra has been involved with PHUSE since 2015, leading and supporting PHUSE projects under the Optimizing the Use of Data Standards and the Real World Evidence Working Groups. Edwin is an active PHUSE member, contributing to the PHUSE EU Connect as a presenter, Stream Chair and Connect Chair, and as a PHUSE Wiki Administrator. He is currently a permanent member of the EU and US Connect Planning Committees.  Sandra and Edwin will be joining the Current Leads, Jane Owens and Janet Low. You can learn more about the new Leads via the Optimizing the Use of Data Standards page. 

The Safety Analytics Working Group also welcome two new Leads: Mac Gordon and Ellis Unger.Mac Gordon has a master’s in statistics and graduate certificates in public health, pharmacovigilance and pharmacoepidemiology and has been with Johnson & Johnson for 15 years and in industry for 20 years. Mac has been involved with lupus research since joining the organisation, with focus areas in late-development immunology and clinical trial safety.Ellis Unger, MD, is a Principal Drug Regulatory Expert at Hyman, Phelps & McNamara, a leading consulting FDA law firm. Dr Unger is a board-certified cardiologist, who retired from the U.S. Food and Drug Administration following a 24-year career, where he served in senior leadership roles in the Office of New Drugs, Center for Drug Evaluation and Research (CDER).  Mac and Dr Unger will be joining Mary Nilsson, Greg Ball and Scott Proestel. You can learn more about the new Leads on theSafety Analyticspage.

Our data standards community, which is comprised of leaders and experts responsible for the governance and implementation of data standards across the biopharmaceutical industry, authored a new white paper, which highlights current challenges in data standardisation across the biopharma industry and identifies opportunities where we can work together to tackle them. 



New Projects This Quarter

A couple of the Working Groups have expanded, with two new projects this quarter. 



Published

It’s been another busy quarter across all eight Working Groups. There have been eight published deliverables, with many more in the works. The published deliverables are: 

Data Standards White Paper 

  • The white paper was authored by members of the PHUSE data standards community, comprised of leaders and experts responsible for the governance and implementation of data standards across the biopharmaceutical industry.  

Ensuring Registry Data Relevance and Reliability for Regulatory Use 

  • The Real World Evidence Working Group project Best Data Practices for Rare Disease Patient Foundations and Researchers published a new deliverable. The poster – ‘Ensuring Registry Data Relevance and Reliability for Regulatory Use’ – focuses on data governance, integrity, fit-for-purpose data, and security/privacy. 

EU CTR Blog – Year 2 Update 

  • The EU CTR Implementation project within the Data Transparency Working Group posted a blog post on EU CTR implementation. 
    The European Union (EU) Clinical Trials Regulation No 536/2014 (‘the Regulation’) has been operational since 31 January 2022. It covers interventional clinical trials of investigational medicinal products for human use and has important impacts on all aspects of trial set-up, operation and reporting in the EU and European Economic Area (EEA). 

QTL White Paper 

Educate the General Population on Data Privacy and Data Sharing 

  • The Educate the General Population on Data Privacy and Data Sharing project within the Data Transparency Working Group have published video 2:What Will I Receive and When Will I Receive It?’ 

SDTM ADAM

RWE Blogs 



Under Review 


Image RemovedImage Added